ArticleLeukemia research2009
Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia.
Article in Leukemia research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 31 citations in OpenAlex.
- Exogenous Heat Shock Proteins in Oncology: Biological Roles and Clinical Implications.Cancers · 2026Review
- Murine Models in Oral Research: A Narrative Review of Experimental Approaches and Cardiovascular Implications.Biology · 2025Review
- Article
- Extracellular cell stress (heat shock) proteins-immune responses and disease: an overview.Philosophical transactions of the Royal Society of London. Series B, Biological sciences · 2018Review
- Overexpression of cytosolic, plasma membrane bound and extracellular heat shock protein 70 (Hsp70) in primary glioblastomas.Journal of neuro-oncology · 2017Article
- Serum Heat Shock Protein 70, as a Potential Biomarker for Small Cell Lung Cancer.Pathology oncology research : POR · 2017Article
- Article
- Heat shock proteins and heat shock factor 1 in carcinogenesis and tumor development: an update.Archives of toxicology · 2013Review
- Apoptosis induced by ZnPcH1-based photodynamic therapy in Jurkat cells and HEL cells.International journal of hematology · 2011Article
- Reproducible enrichment of extracellular heat shock proteins from blood serum using monomeric avidin.Bioorganic & medicinal chemistry letters · 2011Article
- Anti-tumor activity of patient-derived NK cells after cell-based immunotherapy--a case report.Journal of translational medicine · 2009Article
Corrections and comments
- Commented on by
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
We evaluated the association of circulating levels of heat shock protein 70 (Hsp70) in plasma with clinical behavior and progression in 139 chronic myeloid leukemia (CML) patients. Circulating Hsp70 levels did not differ significantly between CML patients in the chronic phase (n=93; median 33.24 ng/mL, range 3.89-128.2 ng/mL) and those in the accelerated/blast phase (n=46; median 26.57 ng/mL, range 4.5-114.7 ng/mL). However, overall CML patients had significantly higher levels of Hsp70 than healthy subjects (n=95, median 4.17 ng/mL, range 1.75-24.7 ng/mL) (P<0.001). In chronic phase CML patients, Hsp70 levels above the median were associated with a higher rate of progression to the accelerated/blast phase and a tendency toward shorter survival. Plasma Hsp70 thus could be a potential marker for predicting disease progression in patients with chronic phase CML.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.